Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  +1.18p +2.42% 50.04p 1,608,113 13:00:14
Bid Price Offer Price High Price Low Price Open Price
50.06p 50.28p 51.18p 48.97p 49.07p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 788.08 218.00 29.80 1.7 364.4

Indivior (INDV) Latest News (1)

More Indivior News
Indivior Takeover Rumours

Indivior (INDV) Share Charts

1 Year Indivior Chart

1 Year Indivior Chart

1 Month Indivior Chart

1 Month Indivior Chart

Intraday Indivior Chart

Intraday Indivior Chart

Indivior (INDV) Discussions and Chat

Indivior Forums and Chat

Date Time Title Posts
24/5/201909:43INDIVIOR THE PILL WITH NO CHEERS OR BEERS1,257
15/5/201915:28RB. de-merger 541
03/5/201910:16Judgement against insys2
31/7/201813:45Indivior (INDV) IP Battle Status -
28/7/201814:16Indivior (INDV) One to Watch on Monday 2

Add a New Thread

Indivior (INDV) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
11:59:0650.17825413.94O
11:50:5550.041,142571.46AT
11:50:4650.14974488.41O
11:50:4350.041,250625.50AT
11:48:0750.2014,5837,320.67O
View all Indivior trades in real-time

Indivior (INDV) Top Chat Posts

DateSubject
24/5/2019
09:20
Indivior Daily Update: Indivior Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 48.86p.
Indivior Plc has a 4 week average price of 35.63p and a 12 week average price of 20.98p.
The 1 year high share price is 504.60p while the 1 year low share price is currently 20.98p.
There are currently 728,306,837 shares in issue and the average daily traded volume is 4,886,336 shares. The market capitalisation of Indivior Plc is £364,444,741.23.
03/5/2019
08:36
jubberjim: Will this judgement in the states adversely affect the share price Am long small amount but would like to know more informed views
01/5/2019
10:27
advfn137: What way is the share price going tmrw after the results?Is it worth buying in now??
17/4/2019
21:22
floridamassive: One thing I don’t understand is after the standard life RNS came out, rather than going up, why the hell share price dropped by 4%?? Surely, it’s a good thing that they increased their stake in INDV!? Doesn’t make any sense? What am I missing here? share price has been behaving very strangely today.
16/4/2019
10:13
floridamassive: This will bounce back over the coming days, this will easily smash 70-80p over the coming weeks, just need to be patient with it. Fines are not going to be anywhere near 3B, GSK was fined $3 bln on 3 of its best-selling drugs that together generated more than $25 bln in sales during the years covered by the settlement, Suboxone Film generated $2.9 bln in total in the investigated years (2010-2014) - This suggests that the $3 bln headline fine is extremely aggressive, applying that logic to INDV, you are looking at ~350M. Therefore, the fall in share price, hence the market cap is way overdone!! Keep the faith and you will be rewarded :).
14/4/2019
07:28
dealy: Basically two scenarios here:a) DoJ case thrown out making a complete farce of the system (huge penalties sought for minor misdemeanors resulting in insane share price volatility and commercial market distortion)b) The penalties are real and have to be paid.In (b) the company would have to put it's US subsidiary into Chapter 11.(a) might eventually arise but it could take 18 months to transpire with (b) being an option the whole time.
12/4/2019
07:22
costax1654x: Once is getting sorted...may be a few years...share price might go to 300-500 p per share
10/4/2019
10:40
rzbrdbe: Indv has always been un-investible because of the litigation hanging over it. Investors have only themselves to blame for not reading Indivior's accounts. The company has been very clear about the possibility of an adverse judgement in note 20 of its latest 2018 accounts (see below). It has carried a provision of $438m for many years, being its estimated costs of any resultant litigation (costs to be shared with Reckitt who have set aside a similar amount), but the political climate has now changed. Yes, you could argue that the 3bn sought by the DOJ is over egged but if 3bn is the outcome then the statement in note 20 of the accounts will become fact: "the Group would not continue in business without taking further necessary measures to reduce its cost base and improve its cash flow" and shareholders equity would be wiped out. Shame, because the company appears to have been doing the right thing since separating from Reckitt by developing the implantable sublocade product, possibly a viable new addition to a solution for the US opioid crisis. Reckitt's management clearly saw this issue too hot to handle in 2014 (they are still on the hook for half, hence the decline of 10% in share price). Indv is still un-investible Note 20: "The Group carries a provision for investigative and antitrust litigation matters of $438m. Substantially all of the provision relates to the U.S. Department of Justice investigation. The Group is in advanced discussions with the Department of Justice about a possible resolution to its investigations, although it cannot predict with any certainty whether, when, or at what cost it will reach an ultimate resolution. Although the total amount of the provision has not changed, the classification between current and non-current has changed due to a shift in management’s best estimate of the timing of payments. In the event the final settlement amount of the DOJ matter is materially higher than the provision or is required to be paid over a shorter period of time, and the Group is further adversely impacted by higher than expected loss of revenue following the ‘at-risk’; launch of generic buprenorphine/naloxone sublingual film products or the failure for new products to meet revenue growth expectations, the Group would not continue in business without taking further necessary measures to reduce its cost base and improve its cash flow"
10/4/2019
08:31
newtothisgame3: #INDV Indivior share price nearly halves on drug scheme allegations https://twitter.com/smallcappick/status/1115879888223920129
21/11/2018
08:05
pwhite73: PWhite731 Oct '18 - 22:32 - 452 of 491 Edit 0 0 0 The writing is on the wall for this company. The share price was trading at 490p in June 2018. There are a number of problems here. 1. The opioid addiction market is too competitive and relatively easy to enter. 2. The injunction against Dr Reddy is only temporary. 3. Donald Trump and the State Department are soon to announce their own nationwide programme to combat opioid addiction in the US. The shares can be traded as it bounces off the bottom but because of the share price you need lots of upfront capital to make any decent money. Those who think the share price is about to mount a recovery are mistaken. When the next set of adverse news is released it will plunge again
01/10/2018
23:32
pwhite73: The writing is on the wall for this company. The share price was trading at 490p in June 2018. There are a number of problems here. 1. The opioid addiction market is too competitive and relatively easy to enter. 2. The injunction against Dr Reddy is only temporary. 3. Donald Trump and the State Department are soon to announce their own nationwide programme to combat opioid addiction in the US. The shares can be traded as it bounces off the bottom but because of the share price you need lots of upfront capital to make any decent money. Those who think the share price is about to mount a recovery are mistaken. When the next set of adverse news is released it will plunge again.
Indivior share price data is direct from the London Stock Exchange
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190524 12:15:37